The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300. These cancers are rare but they are the second most common type of gastrointestinal malignancy and their incidence is increasing. NETs can remain clinically silent for years delaying the diagnosis in a large number of patients. Neuro Endocrine Tumors, also known as NETs, are a group of tumors originating in the neuroendocrine cells of many different organs. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. to facilitate availability of NETSPOT ™ nationally, including Zevacor Pharma Inc., that delivered the NETSPOT ™ injection to Holy Name Medical Center.ġ Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. AAA has partnered with four radiopharmacies in the U.S. in two forms: As a kit for reconstitution using a Ga 68 generator, and as NETSPOT ™ Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. NETSPOT ™ is currently available in the U.S. Most importantly, NETSPOT ™ is a dramatic leap forward in detecting NETs and has greatly enhanced sensitivity versus older techniques. Jacqueline Brunetti, M.D., Medical Director of Radiology at Holy Name observed, “NETSPOT ™ alleviates patient burden by providing a faster procedure, lower radiation exposure and eliminating the need for bowel cleansing while increasing our ability to handle more patients with faster scan acquisition and reduced imaging time. This is the biggest challenge oncologists face with NET patients, due to the complexity of localizing these malignancies.” Giuseppe Condemi, MD, PhD, Medical Director of the Carcinoid Center at Holy Name stated, “NETSPOT ™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients. ![]() I’m thrilled to see better diagnostic tools becoming available and am honored to be the first U.S. Condemi has treated my symptoms because he knew the disease was there, but he couldn't target the location of the cancerous cells with the usual method of detection, which was an Octreoscan – until now. ![]() I’ve had this disease for eight years, and throughout that time, Dr. Beyond the frustration of living with an undetected disease, are the health consequences of delayed treatment. Lynn Reiman the first patient to receive a PET scan with NETSPOT ™ declared, “ NET patients like me typically struggle for years, trying to get an accurate diagnosis because of the nature of this hard-to-detect cancer. 1 Saving just one patient from futile surgery can improve the treatment experience, as well as generate cost savings greater than the cost of providing a year’s worth of NETSPOT ™ injections to every NET patient treated in the same hospital! We are proud to contribute to the introduction of pharmaceutical products that improve patient care, while decreasing healthcare costs. ![]() In a clinical study, NETSPOT ™ demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan. We believe NETSPOT ™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. Stefano Buono, Chief Executive Officer of AAA said, “We are very excited to bring NETSPOT ™, a widely anticipated new imaging product to patients in the U.S. As in all cancer care, earlier detection can be life-saving and almost always improves the quality of life for patients.” to offer a new standard of care for our patients. Michael Maron, President and Chief Executive Officer of Holy Name commented, “In our commitment to provide the latest advancements in cancer diagnosis, I’m proud to say Holy Name is the first in the U.S. Food and Drug Administration (“FDA”) for the preparation of gallium Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors (“NETs”) in adult and pediatric patients using Positron Emission Tomography (“PET“) at Holy Name Medical Center (“Holy Name”) in Teaneck, NJ. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced the first administration of NETSPOT ™, a product recently approved by the U.S. 03, 2016 (GLOBE NEWSWIRE) - Advanced Accelerator Applications S.A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |